These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
183 related articles for article (PubMed ID: 12515186)
1. [The effect of ribozyme RzDS on duck hepatitis B virus]. Li H; Chen W; Xu W Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 1998 Jun; 12(2):118-21. PubMed ID: 12515186 [TBL] [Abstract][Full Text] [Related]
2. [Antisense oligodeoxynucleotide targeted at the pre-s region of DHBV could inhibit virus replication in vivo]. He L; Wu X; Chen C Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 1998 Mar; 12(1):1-4. PubMed ID: 12515159 [TBL] [Abstract][Full Text] [Related]
3. Recombinant vaccinia virus expressing Pre-S/S protein of duck hepatitis B virus and its preliminary use for treatment of persistent infection. Ma ZM; Kong YY; Wang Y; Wen YM Acta Virol; 1996; 40(5-6):311-4. PubMed ID: 9171461 [TBL] [Abstract][Full Text] [Related]
4. Antiviral effects of PNA in duck hepatitis B virus infection model. Chen ZY; Cheng AC; Wang MS; Xu DW; Zeng W; Li Z Acta Pharmacol Sin; 2007 Oct; 28(10):1652-8. PubMed ID: 17883953 [TBL] [Abstract][Full Text] [Related]
5. [Anti-virus effect of hepatocyte stimulating substance (HSS) on duck hepatitis B virus in vivo]. Chen G; Chen J; Liu D; Zhang X; Zhu C; Li Y; Wang L; Yang Y; Cai G; Han F Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 1997 Dec; 11(4):329-32. PubMed ID: 15617240 [TBL] [Abstract][Full Text] [Related]
6. [Inhibitory effect of trisodium phosphonoformate (PFA) on duck hepatitis B virus (DHBV) DNA in vivo]. Chen X; Chen H Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 1997 Sep; 11(3):277-81. PubMed ID: 15617348 [TBL] [Abstract][Full Text] [Related]
7. Covalently closed circular DNA is the predominant form of duck hepatitis B virus DNA that persists following transient infection. Le Mire MF; Miller DS; Foster WK; Burrell CJ; Jilbert AR J Virol; 2005 Oct; 79(19):12242-52. PubMed ID: 16160150 [TBL] [Abstract][Full Text] [Related]
8. Vaccination of ducks with a whole-cell vaccine expressing duck hepatitis B virus core antigen elicits antiviral immune responses that enable rapid resolution of de novo infection. Miller DS; Halpern M; Kotlarski I; Jilbert AR Virology; 2006 May; 348(2):297-308. PubMed ID: 16469347 [TBL] [Abstract][Full Text] [Related]
9. [Inhibition of duck hepatitis B virus DNA replication by antisense phosphorothioate oligodeoxynucleotides in vitro and in vivo]. Dong B; Shao XW; Tao PZ Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2003 Mar; 17(1):25-7. PubMed ID: 12870012 [TBL] [Abstract][Full Text] [Related]
10. [Establishment of an in vivo model for duck hepatitis B virus infection using Hubei duckling]. Hu Q; Fang Y; Zhang ZM; Zhang XY; Zhang ZH; Yang DL Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2008 Apr; 22(2):113-5. PubMed ID: 18574531 [TBL] [Abstract][Full Text] [Related]
11. Enhanced duck hepatitis B virus gene expression following aflatoxin B1 exposure. Barraud L; Guerret S; Chevallier M; Borel C; Jamard C; Trepo C; Wild CP; Cova L Hepatology; 1999 Apr; 29(4):1317-23. PubMed ID: 10094981 [TBL] [Abstract][Full Text] [Related]
12. Antiviral therapy with entecavir combined with post-exposure "prime-boost" vaccination eliminates duck hepatitis B virus-infected hepatocytes and prevents the development of persistent infection. Miller DS; Boyle D; Feng F; Reaiche GY; Kotlarski I; Colonno R; Jilbert AR Virology; 2008 Apr; 373(2):329-41. PubMed ID: 18206204 [TBL] [Abstract][Full Text] [Related]
13. Effects of liver growth factors on hepadnavirus replication in chronically infected duck hepatocytes. Schorr O; Borel C; Trepo C; Zoulim F; Hantz O J Hepatol; 2006 May; 44(5):842-7. PubMed ID: 16458387 [TBL] [Abstract][Full Text] [Related]
14. The development of persistent duck hepatitis B virus infection can be prevented using antiviral therapy combined with DNA or recombinant fowlpoxvirus vaccines. Feng F; Teoh CQ; Qiao Q; Boyle D; Jilbert AR Vaccine; 2010 Oct; 28(46):7436-43. PubMed ID: 20833122 [TBL] [Abstract][Full Text] [Related]
15. DNA vaccines expressing the duck hepatitis B virus surface proteins lead to reduced numbers of infected hepatocytes and protect ducks against the development of chronic infection in a virus dose-dependent manner. Miller DS; Kotlarski I; Jilbert AR Virology; 2006 Jul; 351(1):159-69. PubMed ID: 16624364 [TBL] [Abstract][Full Text] [Related]
16. Alternative methods for validation of cell culture infection with duck hepatitis B virus. Sauerbrei A; Schacke M; Schultz U; Egerer R; Merkle I; Glebe D; Gerlich W; Wutzler P J Virol Methods; 2005 Nov; 129(2):178-85. PubMed ID: 16002155 [TBL] [Abstract][Full Text] [Related]
17. Enhancement of neutralizing humoral response of DNA vaccine against duck hepatitis B virus envelope protein by co-delivery of cytokine genes. Saade F; Buronfosse T; Pradat P; Abdul F; Cova L Vaccine; 2008 Sep; 26(40):5159-64. PubMed ID: 18554756 [TBL] [Abstract][Full Text] [Related]
18. Experimental study on pathogenicity of precore mutants in Hepadnaviridae. Ma Z; Wen Y; Xiong S; Zhai W; He L; Yao X Chin Med J (Engl); 1998 Jun; 111(6):519-23. PubMed ID: 11245071 [TBL] [Abstract][Full Text] [Related]
19. Competition in vivo between a cytopathic variant and a wild-type duck hepatitis B virus. Lenhoff RJ; Luscombe CA; Summers J Virology; 1998 Nov; 251(1):85-95. PubMed ID: 9813205 [TBL] [Abstract][Full Text] [Related]
20. Dominant negative mutants of the duck hepatitis B virus core protein interfere with RNA pregenome packaging and viral DNA synthesis. von Weizsäcker F; Köck J; Wieland S; Offensperger WB; Blum HE Hepatology; 1999 Jul; 30(1):308-15. PubMed ID: 10385672 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]